OSR Holdings Restructures $815M VXM01 License to Capture Parent-Level Value
OSR Holdings restructured its term sheet with BCM Europe AG to make itself direct counterparty for oncology asset VXM01, directing up to $815 million in milestone payments to the parent and reducing subsidiary distributions. The deal includes a $30 million drawdown financing facility and a $15 million equity option.
1. Revised License Structure
Under the updated agreement, OSR Holdings and its Swiss subsidiary Vaximm AG will both serve as direct counterparties to BCM Europe AG’s investment vehicle, replacing the subsidiary-only structure and centralizing global licensing negotiations and obligations at the parent level.
2. Milestone Payments Shift to Parent
The restructure directs up to $815 million in milestone payments, excluding royalties, to OSR Holdings, reducing reliance on upstream distributions and ensuring that clinical progress milestones translate directly into parent-level value.
3. $30M Drawdown Financing Facility
OSR Holdings will provide a $30 million development financing facility to Vaximm AG, enabling drawdowns tied to clinical program needs and enhancing capital efficiency by aligning funding with developmental milestones.
4. Equity Option, Digital Assets and Timeline
OSR Holdings retains an option to issue up to $15 million of common stock at $10 per share, exercisable six months after signing, defers digital asset financing provisions pending regulatory clarity, and targets a definitive agreement by April 30, 2026.